A dream life post COVID will soon be a reality

about us

At Coronavax, we are applying the principles of Immuno-Oncology to treat long covid so that you can have a pain free life

about long covid

What?

Long COVID is a condition where COVID-19 symptoms persist long after the initial infection has cleared. These symptoms, lasting for months to years, can significantly impact daily life.

Who?

An estimated 1 in 13 adults in the U.S. (7.5%) have Long COVID symptoms. At least 65M persons worldwide, about 30-75% of recovering patients, are affected. Each new infection can increase the risk of developing Long COVID.

Why?

Harvard University estimates that the total economic cost of long COVID is $3.7 trillion. That’s $11,000 per capita or 17% of the 2019 gross domestic product (GDP).

Our story so far

2021

2021

2021

  • March: Company Formed

  • August: US PTO patent filing Utility

  • March: Company Formed

  • August: US PTO patent filing Utility

  • March: Company Formed

  • August: US PTO patent filing Utility

2022

2022

2022

  • February: Seed Funding Closed

  • August: PCT Patent Filing

  • December: Coronavax is presented at World Vaccine Congress, San Diego, CA

  • February: Seed Funding Closed

  • August: PCT Patent Filing

  • December: Coronavax is presented at World Vaccine Congress, San Diego, CA

  • February: Seed Funding Closed

  • August: PCT Patent Filing

  • December: Coronavax is presented at World Vaccine Congress, San Diego, CA

December, 2022

December, 2022

December, 2022

CVAX-001 manufactured in lab

CVAX-001 manufactured in lab

CVAX-001 manufactured in lab

2023

2023

2023

  • March: Testing of CVAX-001 in C57 mice begins

  • June: Mouse tests completed

  • March: Testing of CVAX-001 in C57 mice begins

  • June: Mouse tests completed

  • March: Testing of CVAX-001 in C57 mice begins

  • June: Mouse tests completed

2024

2024

2024

  • January: Coronavax converted to Delaware C-Corporation

  • March: Long COVID hamster tests at MRI BSL-3 labs begins

  • January: Coronavax converted to Delaware C-Corporation

  • March: Long COVID hamster tests at MRI BSL-3 labs begins

  • January: Coronavax converted to Delaware C-Corporation

  • March: Long COVID hamster tests at MRI BSL-3 labs begins

What is CVAX-001?

What is CVAX-001?

CVAX-001 is an intranasal therapeutic designed to reprogram the immune response to Long COVID

CVAX-001 is an intranasal therapeutic designed to reprogram the immune response to Long COVID

Our team

Experts with a proven healthcare history

Experts with a proven healthcare history

Bruce Lyday

CEO

30 years of research in cancer immunotherapy and experience as a Former Oncology Trials Director

Bruce Lyday

CEO

30 years of research in cancer immunotherapy and experience as a Former Oncology Trials Director

Bruce Lyday

CEO

30 years of research in cancer immunotherapy and experience as a Former Oncology Trials Director

Adam Ruskin, Ph.D, D.V.M

VP, Clinical Operations 

Former clinical lead for Moderna Former Epidemiologist, C.D.C.

Adam Ruskin, Ph.D, D.V.M

VP, Clinical Operations 

Former clinical lead for Moderna Former Epidemiologist, C.D.C.

Adam Ruskin, Ph.D, D.V.M

VP, Clinical Operations 

Former clinical lead for Moderna Former Epidemiologist, C.D.C.

Robert Hopkins, M.D

Chief Medical Officer (CMO)

Former FDA Reviewer, and Senior Medical Adviser at BARDA and has 20+ vaccines developed

Robert Hopkins, M.D

Chief Medical Officer (CMO)

Former FDA Reviewer, and Senior Medical Adviser at BARDA and has 20+ vaccines developed

Robert Hopkins, M.D

Chief Medical Officer (CMO)

Former FDA Reviewer, and Senior Medical Adviser at BARDA and has 20+ vaccines developed

Matt Gawin, M.B.A

Chief Financial Officer (CFO)

Strategic Planning GE Capital-Information Systems

Matt Gawin, M.B.A

Chief Financial Officer (CFO)

Strategic Planning GE Capital-Information Systems

Matt Gawin, M.B.A

Chief Financial Officer (CFO)

Strategic Planning GE Capital-Information Systems

Founder's Note

Hey everyone,

I’m Bruce, CEO here at Coronavax.

Long COVID affects an estimated 100 million people, leaving many with few treatment options and a quality of life often worse than that of advanced cancer patients. A consensus is emerging that Long COVID is an inflammatory condition caused by the immune system's failure to completely eliminate the virus. This issue is made worse by the virus hiding in mucosal and fatty tissues, which are notoriously hard for drugs to reach.

Drawing inspiration from cancer immunotherapy, which has successfully cured thousands by stimulating the immune system, we're bringing this revolutionary science to Long COVID. At Coronavax, we focus on mucosal immunity to target and eliminate the virus without causing excessive inflammation.

Just as immunotherapy has transformed cancer treatment, we aim to do the same for Long COVID. We believe in the potential of our approach and are dedicated to making a difference.

Together, we can bring hope and healing to millions. Join us.

Best,
Bruce Lyday

FAQs

What is Long COVID?

What causes Long COVID?

How is Long COVID treated?

Why is Long COVID so difficult to treat with drugs?

How is CVAX-001 designed to work?

What is Long COVID?

What causes Long COVID?

How is Long COVID treated?

Why is Long COVID so difficult to treat with drugs?

How is CVAX-001 designed to work?

What is Long COVID?

What causes Long COVID?

How is Long COVID treated?

Why is Long COVID so difficult to treat with drugs?

How is CVAX-001 designed to work?

Join us in fighting Long Covid

We are looking for investors to help fund the mission.

With care and love from California

These statements have not been evaluated by the Food and Drug Administration. No product regulated under PDUFA can be promoted as safe and effective for treating any disease until it has been tested in human clinical trials and approved for sale by the FDA. CVAX-001 is currently in the Pre-Clinical testing phase.

With care and love from California

These statements have not been evaluated by the Food and Drug Administration. No product regulated under PDUFA can be promoted as safe and effective for treating any disease until it has been tested in human clinical trials and approved for sale by the FDA. CVAX-001 is currently in the Pre-Clinical testing phase.

With care and love from California

These statements have not been evaluated by the Food and Drug Administration. No product regulated under PDUFA can be promoted as safe and effective for treating any disease until it has been tested in human clinical trials and approved for sale by the FDA. CVAX-001 is currently in the Pre-Clinical testing phase.

© 2024 | Coronavax Inc.

© 2024 | Coronavax Inc.

© 2024 | Coronavax Inc.